As for cytokine-targeted therapies, results of randomized, placebo-controlled, blinded trials targeting either IL-1 or IL-6 pathway showed no survival benefit in COVID-19 patients ([73] and [74], respectively), unless performed in combination with cortisteroids (75, 76), suggesting that inhibiting a single cytokine pathway might not be sufficient. The gene discussed is IL6; the disease is COVID-19.